Merck’s Keytruda Gets FDA’s Priority Tag in Bladder Cancer
Merck & Co., Inc. MRK announced that the FDA has granted priority review status to yet another supplemental new drug application (sNDA) for its blockbuster PD-L1 inhibitor, Keytruda. The sNDA is seeking approval of Keytruda, as a monotherapy, to treat patients with high-risk non-muscle invasive bladder cancer (NMIBC), unresponsive to Bacillus Calmette-Guerin (BCG) therapy – a therapy widely used in the management of bladder cancer. […]